---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-069153"
form_type: "8-K"
ticker: "BOLT"
cik: "0001641281"
company_name: "Bolt Biotherapeutics, Inc."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-21T23:46:01.993624+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bolt Biotherapeutics Q1 2025: operating loss $12.1M; cash $58M; BDC-4182 Phase 1 open

## Summary
- Collaboration revenue $1.2M (down from $5.3M in Q1 2024) due to completion of Innovent agreement.
- R&D expense $9.5M (down from $16.5M); G&A $3.8M (down from $5.8M) reflecting May 2024 restructuring.
- Cash balance $58.0M expected to fund operations and milestones through mid-2026.
- BDC-4182 Phase 1 dose-escalation study for gastric/gastroesophageal cancer opened for enrollment in April 2025.
- Partnering process initiated for BDC-3042 after AACR 2025 data showed favorable safety and biological activity.

## SEC filing metadata
- accession: 0000950170-25-069153
- form_type: 8-K
- ticker: BOLT
- cik: 0001641281
- company_name: Bolt Biotherapeutics, Inc.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641281/000095017025069153/0000950170-25-069153-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641281/000095017025069153/bolt-20250512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-069153
- JSON: https://secwatch.observer/filing/0000950170-25-069153.json
- Plain text: https://secwatch.observer/filing/0000950170-25-069153.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.